Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ISIS EIF4E Rx · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part 1 Cohort 1 | EXPERIMENTAL | - |
| Part 1 Cohort 2 | EXPERIMENTAL | - |
| Part 2 Arm A | EXPERIMENTAL | - |
| Part 2 Arm B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ISIS EIF4E Rx | DRUG | 800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle. |
| Prednisone | DRUG | 5 mg administered orally twice daily on days 1, 8, 15 and 22 of each cycle |
| Docetaxel | DRUG | 75 mg/m2 administered as a 1-hour intravenous infusion on day 1 of each cycle |
| Paclitaxel | DRUG | 200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle |
| Carboplatin | DRUG | AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle |
Inclusion Criteria: * Provide written informed consent prior to Screening. * Age ≥ 18 years. * Histological or cytological diagnosis of adenocarcinoma of the prostate. * Metastatic disease for which no curative therapy exists and for which systemic chemotherapy is indicated. * Progression of diseas...
ISIS EIF4E Rx is an investigational small molecule being studied for the treatment of castrate-resistant prostate cancer and non-small cell lung cancer. It is in Phase 1 clinical development and is not approved by the FDA.
ISIS EIF4E Rx is being developed by Ionis Pharmaceuticals, Inc., which trades under the ticker symbol IONS on the NASDAQ.
ISIS EIF4E Rx is in Phase 1 clinical development. It has completed two Phase 1 trials, one in castrate-resistant prostate cancer and one in non-small cell lung cancer, and remains investigational.
ISIS EIF4E Rx has been studied in two completed Phase 1 trials. NCT01234025 evaluated it in combination with docetaxel and prednisone in castrate-resistant prostate cancer, and NCT01234038 evaluated it with carboplatin and paclitaxel in non-small cell lung cancer.
No alternative names for ISIS EIF4E Rx have been reported. It is referred to by this name in clinical trial records and is distinct from other investigational agents.